KR20220123742A - Hdac 억제제와 pd-l1 억제제의 병용 요법 - Google Patents
Hdac 억제제와 pd-l1 억제제의 병용 요법 Download PDFInfo
- Publication number
- KR20220123742A KR20220123742A KR1020227029531A KR20227029531A KR20220123742A KR 20220123742 A KR20220123742 A KR 20220123742A KR 1020227029531 A KR1020227029531 A KR 1020227029531A KR 20227029531 A KR20227029531 A KR 20227029531A KR 20220123742 A KR20220123742 A KR 20220123742A
- Authority
- KR
- South Korea
- Prior art keywords
- sti
- administered
- compound
- cancer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335056P | 2016-05-11 | 2016-05-11 | |
| US62/335,056 | 2016-05-11 | ||
| PCT/US2017/032200 WO2017197140A1 (en) | 2016-05-11 | 2017-05-11 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| KR1020187035902A KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035902A Division KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220123742A true KR20220123742A (ko) | 2022-09-08 |
Family
ID=60267123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227029531A Ceased KR20220123742A (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제와 pd-l1 억제제의 병용 요법 |
| KR1020187035902A Active KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187035902A Active KR102471590B1 (ko) | 2016-05-11 | 2017-05-11 | Hdac 억제제 및 pd-l1 억제제의 병용 요법 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10385131B2 (enExample) |
| EP (1) | EP3454843A4 (enExample) |
| JP (2) | JP7013388B2 (enExample) |
| KR (2) | KR20220123742A (enExample) |
| CN (1) | CN109640985A (enExample) |
| AU (2) | AU2017264857B2 (enExample) |
| BR (1) | BR112018073328A2 (enExample) |
| CA (1) | CA3023546A1 (enExample) |
| EA (1) | EA201892581A1 (enExample) |
| IL (1) | IL262808B2 (enExample) |
| MA (1) | MA44990A (enExample) |
| MX (2) | MX390986B (enExample) |
| NZ (1) | NZ748058A (enExample) |
| TW (1) | TWI794171B (enExample) |
| WO (1) | WO2017197140A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| WO2014018979A1 (en) | 2012-07-27 | 2014-01-30 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| IL278423B2 (en) | 2015-02-26 | 2024-04-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| SG11201707383PA (en) | 2015-03-13 | 2017-10-30 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| EP3400009A2 (en) * | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| GB2567362B (en) | 2016-07-15 | 2022-04-20 | Nantkwest Inc | HDAC inhibitors for use with NK cell based therapies |
| CA3039451A1 (en) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| WO2019025554A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3 (2H) -ONE DERIVATIVES AS INHIBITORS OF PDE3A AND PDE3B FOR THE TREATMENT OF CANCER |
| EA039417B1 (ru) | 2017-08-07 | 2022-01-25 | Родин Терапеутикс, Инк. | Бициклические ингибиторы гистондеацетилазы |
| NZ749727A (en) | 2018-01-05 | 2020-07-31 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| CN112135610A (zh) * | 2018-01-12 | 2020-12-25 | KDAc治疗股份有限公司 | 用于治疗癌症的选择性组蛋白去乙酰酶3(hdac3)抑制剂及免疫治疗剂的组合 |
| JP2021511293A (ja) * | 2018-01-12 | 2021-05-06 | ビラクタ セラピューティクス，インク． | 細胞免疫療法で使用されるエピジェネティック修飾因子 |
| EP3820859B1 (en) * | 2018-07-13 | 2024-03-20 | Alkermes, Inc. | Inhibitors of histone deacetylase |
| EP3884944A4 (en) * | 2018-11-20 | 2022-08-31 | Shenzhen Chipscreen Biosciences Co., Ltd. | USE OF CHIDAMID |
| TWI750573B (zh) | 2019-02-01 | 2021-12-21 | 德商拜耳廠股份有限公司 | 1,2,4-三-3(2h)-酮化合物 |
| KR20220003528A (ko) * | 2019-04-01 | 2022-01-10 | 호운 사이먼 샤 | 암 면역요법을 위한 조성물 및 방법 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| US11878009B2 (en) * | 2019-09-10 | 2024-01-23 | Great Novel Therapeutics Biotech & Medicals Corporation | Anticancer combination of chidamide and celecoxib salts |
| TW202114659A (zh) * | 2019-10-02 | 2021-04-16 | 德商４Ｓｃ製藥公司 | 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合 |
| WO2021092190A1 (en) * | 2019-11-05 | 2021-05-14 | Health Research, Inc. | Combination therapy for cancer |
| TW202128224A (zh) * | 2019-12-23 | 2021-08-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法 |
| WO2022046792A2 (en) * | 2020-08-25 | 2022-03-03 | Huyabio International, Llc | Methods and compositions for genetic modulation of tumor microenvironments |
Family Cites Families (538)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH627446A5 (fr) | 1978-01-17 | 1982-01-15 | Debiopharm Sa | Nouveaux derives de la benzamide. |
| GB8302483D0 (en) | 1983-01-29 | 1983-03-02 | Beecham Group Plc | Compounds |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| CZ284687B6 (cs) | 1986-04-30 | 1999-02-17 | Dainippon Pharmaceutical Co., Ltd. | Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2529912B2 (ja) | 1990-10-16 | 1996-09-04 | 帝国化学産業株式会社 | ベンズアミド誘導体 |
| US5395832A (en) | 1991-02-15 | 1995-03-07 | Hokuriku Seiyaku Co., Ltd. | Benzamide derivatives |
| TW219935B (enExample) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| US5236931A (en) | 1992-03-26 | 1993-08-17 | A. H. Robins Company, Incorporated | 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol |
| US5610052A (en) | 1992-08-26 | 1997-03-11 | Ribozyme Pharmaceuticals Inc. | Enzymatic RNA with activity to ras |
| EP0757985A4 (en) | 1994-04-28 | 1997-09-03 | Yamanouchi Pharma Co Ltd | N- (3-PYRROLIDINYL) BENZAMIDE DERIVATIVE |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| JPH0823980A (ja) | 1994-07-15 | 1996-01-30 | Terumo Corp | 脳神経細胞のアポトーシス時に発現する核レセプターおよびそれをコードする核レセプター遺伝子 |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5958792A (en) | 1995-06-07 | 1999-09-28 | Chiron Corporation | Combinatorial libraries of substrate-bound cyclic organic compounds |
| GB9525620D0 (en) | 1995-12-15 | 1996-02-14 | Glaxo Group Ltd | Chemical compounds |
| EP0827742A1 (en) | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| GB9821483D0 (en) | 1998-10-03 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| GB9625145D0 (en) | 1996-12-03 | 1997-01-22 | Smithkline Beecham Plc | Novel compounds |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| JPH10330254A (ja) | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
| US6444849B1 (en) | 1997-06-25 | 2002-09-03 | Mitsubishi Chemical Corporation | Amide derivatives |
| WO1999005109A1 (en) | 1997-07-25 | 1999-02-04 | Tsumura & Co. | PYRIDYLACRYLAMIDE DERIVATIVES AND NEPHRITIS REMEDIES AND TGF-β INHIBITORS CONTAINING THE SAME |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| US6673827B1 (en) | 1999-06-29 | 2004-01-06 | The Uab Research Foundation | Methods of treating fungal infections with inhibitors of NAD synthetase enzyme |
| JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
| CN1188389C (zh) | 1998-05-15 | 2005-02-09 | 阿斯特拉曾尼卡有限公司 | 用于治疗由细胞因子引起的疾病的苯甲酰胺衍生物 |
| ATE272633T1 (de) | 1998-12-23 | 2004-08-15 | Lilly Co Eli | Aromatische amiden |
| JP2000256194A (ja) | 1999-01-06 | 2000-09-19 | Mitsui Chemicals Inc | 核内レセプタ作動薬およびその効果増強剤 |
| AU3857300A (en) | 1999-02-11 | 2000-08-29 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| DK1163212T3 (da) | 1999-03-17 | 2005-11-14 | Astrazeneca Ab | Amidderivater |
| IL145509A0 (en) | 1999-03-19 | 2002-06-30 | Vertex Pharma | Oral butyrate compositions |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| AU6932700A (en) | 1999-09-08 | 2001-04-10 | Sloan-Kettering Institute For Cancer Research | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| JP4360660B2 (ja) | 1999-11-09 | 2009-11-11 | 三井化学株式会社 | モノアシルフェニレンジアミン誘導体の精製法 |
| JP2003516150A (ja) | 1999-12-08 | 2003-05-13 | ジェンセット | 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
| US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
| EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| CA2423868C (en) | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
| US7993626B2 (en) | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| ZA200500418B (en) | 2002-07-17 | 2006-10-25 | Titan Pharmaceuticals Inc | Combination of chemotherapeutic drugs for increasing anitumor activity |
| US20050215601A1 (en) | 2002-09-25 | 2005-09-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient |
| US8163896B1 (en) | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20050054647A1 (en) | 2002-12-27 | 2005-03-10 | Detlev Schuppan | New pharmaceutical combination |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
| CN1284772C (zh) | 2003-07-04 | 2006-11-15 | 深圳微芯生物科技有限责任公司 | 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂 |
| WO2005049105A2 (en) | 2003-11-10 | 2005-06-02 | Angiotech International Ag | Medical implants and anti-scarring agents |
| US20130189364A1 (en) | 2004-07-09 | 2013-07-25 | Robert Sabin | Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| AU2006218359A1 (en) | 2005-03-04 | 2006-09-08 | John O'neil | Adult pancreatic derived stromal cells |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| WO2006121522A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions |
| WO2006121518A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Electrical devices, anti-scarring agents, and therapeutic compositions |
| WO2006135479A2 (en) | 2005-05-10 | 2006-12-21 | Angiotech International Ag | Anti-scarring agents, therapeutic compositions, and use thereof |
| WO2006121521A2 (en) | 2005-05-10 | 2006-11-16 | Angiotech International Ag | Soft tissue implants, anti-scarring agents, and therapeutic compositions |
| WO2007057440A2 (en) | 2005-11-17 | 2007-05-24 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2007075414A2 (en) | 2005-12-14 | 2007-07-05 | The Trustees Of Columbia University In The City Of New York | Chemically derivatized cd4 and uses thereof |
| WO2007122369A2 (en) | 2006-04-13 | 2007-11-01 | Oncomethylome Sciences Sa | Novel tumour suppressor |
| WO2008012692A2 (en) | 2006-05-26 | 2008-01-31 | Methylgene Inc. | Assay for efficacy of histone deacetylase inhibitors |
| EP2457913B1 (en) | 2006-10-19 | 2017-04-19 | Signal Pharmaceuticals, LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EA201201640A1 (ru) | 2007-01-30 | 2013-09-30 | Фармасайкликс, Инк. | Способы определения устойчивости рака к ингибиторам гистондеацетилазы |
| CN101784564B (zh) | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-dc变体 |
| CN101821279A (zh) | 2007-08-15 | 2010-09-01 | 赛特凯恩蒂克公司 | 某些化学个体、组合物和方法 |
| JP2010539104A (ja) | 2007-09-14 | 2010-12-16 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 |
| GB0802009D0 (en) | 2008-02-04 | 2008-03-12 | Chroma Therapeutics Ltd | Biomarkers of aminopeptidase inhibition |
| JP2009209090A (ja) | 2008-03-04 | 2009-09-17 | Mitsui Chemicals Inc | 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法 |
| EP2283862B1 (en) | 2008-06-02 | 2018-08-08 | The University of Tokyo | Combination treatment of cancer comprising anti-mfg-e8 antibody |
| EP2662383A1 (en) | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| US20160041153A1 (en) | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
| CN101757626B (zh) | 2008-12-26 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| CN101756957B (zh) | 2008-12-26 | 2012-11-14 | 鼎泓国际投资（香港）有限公司 | 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| US9028833B2 (en) | 2012-12-13 | 2015-05-12 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| CN101837129B (zh) | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| CN101836989B (zh) | 2009-03-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| US20160186266A1 (en) | 2009-10-27 | 2016-06-30 | Carislife Sciences, Inc. | Molecular profiling for personalized medicine |
| CA2779424A1 (en) | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
| EP2499486A4 (en) | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER |
| WO2011063309A1 (en) | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN107098958B (zh) | 2010-03-26 | 2021-11-05 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8993622B2 (en) | 2010-06-11 | 2015-03-31 | Eirium Ab | Antiviral compounds |
| US20120010230A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling |
| US20120010229A1 (en) | 2010-07-08 | 2012-01-12 | Macdougall John R | Therapeutic regimens for hedgehog-associated cancers |
| EP2606353A4 (en) | 2010-08-18 | 2014-10-15 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASES |
| CN102441167B (zh) | 2010-10-12 | 2014-05-07 | 鼎泓国际投资（香港）有限公司 | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 |
| US9808434B2 (en) | 2011-01-27 | 2017-11-07 | City Of Hope | Compound for treating cancer and diabetes |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| WO2012167086A2 (en) | 2011-06-03 | 2012-12-06 | President And Fellows Of Harvard College | Methods of diagnosing and treating amyotrophic lateral sclerosis |
| JP2014526032A (ja) | 2011-06-07 | 2014-10-02 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 癌に対する循環バイオマーカー |
| EP2721179A4 (en) | 2011-06-16 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | BIOMARKER COMPOSITIONS AND METHOD THEREFOR |
| WO2013028907A1 (en) | 2011-08-23 | 2013-02-28 | Infinity Pharmaceuticals, Inc. | Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof |
| WO2013039956A2 (en) | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating mood disorders |
| JP2014532053A (ja) | 2011-09-30 | 2014-12-04 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 治療用ペプチド |
| ES2784194T3 (es) | 2011-11-30 | 2020-09-23 | Ludwig Inst For Cancer Res Ltd | Moduladores de células iNKT y métodos para uso el mismo |
| WO2013085902A1 (en) | 2011-12-05 | 2013-06-13 | The University Of Texas M.D. | Combination therapy methods for treating an inflammatory breast cancer |
| KR20140126357A (ko) | 2012-02-01 | 2014-10-30 | 컴퓨젠 엘티디. | C1orf32 항체 및 이의 암 치료를 위한 용도 |
| WO2013124867A1 (en) | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules |
| US20150152474A1 (en) | 2012-03-09 | 2015-06-04 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| US10501499B2 (en) | 2012-06-06 | 2019-12-10 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
| CN104717974A (zh) | 2012-06-06 | 2015-06-17 | 比奥诺尔免疫有限公司 | 疫苗 |
| US20140294765A1 (en) | 2012-06-21 | 2014-10-02 | Compugen Ltd. | Lsr antibodies, and uses thereof for treatment of cancer |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| EP4218935A1 (en) | 2012-08-13 | 2023-08-02 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| MX375442B (es) | 2012-09-21 | 2025-03-06 | Intensity Therapeutics Inc | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. |
| HK1214628A1 (zh) | 2012-11-05 | 2016-07-29 | Pronai Therapeutics, Inc. | 寡核苷酸癌症療法的給藥和施用 |
| ES2620119T3 (es) | 2012-11-16 | 2017-06-27 | Merck Patent Gmbh | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa |
| AU2013347838A1 (en) | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| CN103833626B (zh) | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
| MX2015006516A (es) | 2012-11-29 | 2015-08-14 | Merck Patent Gmbh | Derivados de azaquinolin-carboxamida. |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| WO2014122551A1 (en) | 2013-02-07 | 2014-08-14 | Koninklijke Philips N.V. | A lighting system having a controller that contributes to a selected light scene, and a method for controlling such a system |
| CA2895284A1 (en) | 2013-02-07 | 2014-08-14 | Immunomedics, Inc. | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CN104056270B (zh) | 2013-02-21 | 2018-11-09 | 中国人民解放军军事医学科学院野战输血研究所 | 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂 |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| WO2014135245A1 (en) | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| PL2970473T3 (pl) | 2013-03-14 | 2018-01-31 | Bristol Myers Squibb Co | Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania |
| JP2016517420A (ja) | 2013-03-14 | 2016-06-16 | セラゴン ファーマシューティカルズ， インク． | 多環式エストロゲン受容体モジュレーター及びその使用 |
| US20160040163A1 (en) | 2013-03-15 | 2016-02-11 | Pronai Therapeutics, Inc. | Dnai for the modulation of genes |
| NZ629816A (en) | 2013-03-15 | 2017-07-28 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CN104069106A (zh) | 2013-03-27 | 2014-10-01 | 南通瑞思医药技术有限公司 | 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用 |
| EP2986303B1 (en) | 2013-04-18 | 2020-02-26 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US20160095850A1 (en) | 2013-05-24 | 2016-04-07 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| WO2014193999A2 (en) | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
| PE20160157A1 (es) | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | Moduladores de los receptores de estrogeno y sus usos |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
| EP3024456A4 (en) | 2013-07-26 | 2017-04-12 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| EP3027599B1 (en) | 2013-07-29 | 2017-04-19 | Merck Patent GmbH | 1,3-disubstituted cyclopentane derivatives |
| US9751832B2 (en) | 2013-07-30 | 2017-09-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
| JP6423875B2 (ja) | 2013-07-31 | 2018-11-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オキソキナゾリニル−ブタンアミド誘導体 |
| JP2016527303A (ja) | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害 |
| BR112016001928B1 (pt) | 2013-08-07 | 2022-07-19 | Merck Patent Gmbh | Derivados de piperidina ureia, seu uso, medicamentos, e kit |
| US20160201063A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
| CN103432077A (zh) | 2013-08-21 | 2013-12-11 | 北京淦航医药科技有限公司 | 西达苯胺固体分散制剂 |
| US10966998B2 (en) | 2013-09-05 | 2021-04-06 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
| CA2922805A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd. | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US20150094518A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Modular polymer platform for the treatment of cancer |
| HRP20191430T1 (hr) | 2013-10-21 | 2019-11-01 | Merck Patent Gmbh | Spojevi heteroarila kao inhibitori btk i njihove uporabe |
| CA2965114A1 (en) | 2013-10-21 | 2015-04-30 | Hemoshear, Llc | In vitro model for a tumor microenvironment |
| US20170080093A1 (en) | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
| AP2016009156A0 (en) | 2013-10-25 | 2016-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| KR20210063475A (ko) | 2013-11-07 | 2021-06-01 | 데시페라 파마슈티칼스, 엘엘씨. | 암치료에 유용한 tie2 키나아제의 억제 방법 |
| EP3068443B1 (en) | 2013-11-12 | 2019-04-10 | Centre for Probe Development and Commercialization | Residualizing linkers and uses thereof |
| AU2014348657A1 (en) | 2013-11-13 | 2016-05-19 | Novartis Ag | mTOR inhibitors for enhancing the immune response |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| ES2860695T3 (es) | 2013-11-18 | 2021-10-05 | Forma Therapeutics Inc | Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US10106611B2 (en) | 2013-12-06 | 2018-10-23 | Dana-Farber Cancer Institute, Inc. | Antibodies that bind to MHC class I polypeptide-related sequence A |
| WO2015086738A2 (en) | 2013-12-11 | 2015-06-18 | Bionor Immuno As | Hiv vaccine |
| WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| US20160263092A1 (en) | 2013-12-19 | 2016-09-15 | Twi Biotechnology, Inc. | Therapeutic uses of berberine formulations |
| KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| CN109336883B (zh) | 2013-12-20 | 2022-06-14 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| HUE037606T2 (hu) | 2013-12-23 | 2018-09-28 | Merck Patent Gmbh | Imidazopirazinon-származékok |
| PE20160996A1 (es) | 2013-12-23 | 2016-11-09 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CN104771363A (zh) | 2014-01-14 | 2015-07-15 | 深圳微芯生物科技有限责任公司 | 一种西达本胺固体分散体及其制备方法与应用 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015110659A1 (en) | 2014-01-27 | 2015-07-30 | Bionor Immuno As | Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response |
| EP3099318A1 (en) | 2014-01-27 | 2016-12-07 | Bionor Immuno AS | Dosage regimen for hiv vaccine |
| EP3099322A1 (en) | 2014-01-27 | 2016-12-07 | Bionor Immuno AS | Method for the vaccination against hiv |
| US9631013B2 (en) | 2014-01-28 | 2017-04-25 | Fibrogen, Inc. | Therapeutic method for pancreatic cancer |
| WO2015113927A1 (en) | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP3099682A1 (en) | 2014-01-29 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| US10619210B2 (en) | 2014-02-07 | 2020-04-14 | The Johns Hopkins University | Predicting response to epigenetic drug therapy |
| US9676757B2 (en) | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| EP3110824A4 (en) | 2014-02-28 | 2017-11-29 | The Royal Institution for the Advancement of Learning / McGill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| SG10201807838SA (en) | 2014-03-11 | 2018-10-30 | Council Queensland Inst Medical Res | Determining cancer aggressiveness, prognosis and responsiveness to treatment |
| AU2015228859A1 (en) | 2014-03-13 | 2016-07-07 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| RU2016137150A (ru) | 2014-03-13 | 2018-04-18 | Ф. Хоффманн-Ля Рош Аг | Способы и композиции для модулирования мутантов эстрогеновых рецепторов |
| ES2770684T3 (es) | 2014-03-14 | 2020-07-02 | Novartis Ag | Moléculas de anticuerpos contra LAG-3 y usos de los mismos |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| CN104974079A (zh) | 2014-04-02 | 2015-10-14 | C&C生物医药有限公司 | 苯胺相关化合物的酰胺衍生物及其组合物 |
| WO2015153948A2 (en) | 2014-04-03 | 2015-10-08 | University Of Maryland, Baltimore | Microtentacle imaging in patient tumor samples |
| CN106916100B (zh) | 2014-04-04 | 2020-09-15 | 深圳微芯生物科技股份有限公司 | 一种e构型苯甲酰胺类化合物及其药用制剂 |
| US9987258B2 (en) | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 | ||
| JP2015209376A (ja) | 2014-04-24 | 2015-11-24 | 国立大学法人北海道大学 | 腫瘍特異的免疫増強剤 |
| WO2015168465A1 (en) | 2014-04-30 | 2015-11-05 | Rgenix, Inc. | Inhibitors of creatine transport and uses thereof |
| WO2015168614A2 (en) | 2014-05-01 | 2015-11-05 | Board Of Regents Of The University Of Nebraska | Polymer compositions of histone deacetylase inhibitors and methods of use thereof |
| WO2015172747A1 (en) | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| WO2015184405A1 (en) | 2014-05-30 | 2015-12-03 | Medivation Technologies, Inc. | Aromatic compounds, compositions and uses thereof |
| WO2015191568A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| TWI681954B (zh) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺 |
| WO2015191743A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors |
| ES2833025T3 (es) | 2014-06-13 | 2021-06-14 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa |
| SG11201609877XA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| EA201692267A1 (ru) | 2014-06-13 | 2017-06-30 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
| CN106573922A (zh) | 2014-06-13 | 2017-04-19 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| JP6527534B2 (ja) | 2014-06-16 | 2019-06-05 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | ヒストンメチルトランスフェラーゼ及びｄｎａメチルトランスフェラーゼの二重阻害剤としての新規化合物 |
| UY36175A (es) | 2014-06-17 | 2016-01-29 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| NO2717902T3 (enExample) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| WO2015200352A1 (en) | 2014-06-24 | 2015-12-30 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US10273311B2 (en) | 2014-06-26 | 2019-04-30 | Yale University | Compositions to regulate renalase in the treatment of diseases and disorders |
| PT3166607T (pt) | 2014-07-11 | 2022-12-07 | Gilead Sciences Inc | Moduladores de receptores de tipo toll para o tratamento do vih |
| US20170165321A1 (en) | 2014-07-11 | 2017-06-15 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
| AU2015289922A1 (en) | 2014-07-15 | 2017-02-16 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| CN104083763A (zh) | 2014-07-16 | 2014-10-08 | 中国人民解放军军事医学科学院野战输血研究所 | 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用 |
| CN106817900A (zh) | 2014-07-17 | 2017-06-09 | 默克专利有限公司 | 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途 |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| CA2955878A1 (en) | 2014-07-25 | 2016-01-28 | Bayer Pharma Aktiengesellschaft | Amino-substituted isoxazoles |
| EP3174974B1 (en) | 2014-07-29 | 2020-05-20 | Novartis AG | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3177292B1 (en) | 2014-08-07 | 2020-11-25 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| GB201414464D0 (en) | 2014-08-14 | 2014-10-01 | Technion Res & Dev Foundation | Compositions and methods for therapeutics prescreening |
| AU2015304438B2 (en) | 2014-08-18 | 2019-06-20 | Ono Pharmaceutical Co., Ltd. | Acid-addition salt of Trk-inhibiting compound |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN106573133B (zh) | 2014-08-19 | 2020-03-03 | 加利福尼亚大学董事会 | 用于局部药物递送的植入物及其使用方法 |
| JP2017525721A (ja) | 2014-08-26 | 2017-09-07 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品 |
| ES2695700T3 (es) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirales |
| US20160067255A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| RU2718914C2 (ru) | 2014-09-13 | 2020-04-15 | Новартис Аг | Сочетанные способы лечения с использованием ингибиторов alk |
| PT3194401T (pt) | 2014-09-16 | 2020-12-23 | Gilead Sciences Inc | Formas sólidas de modulador de recetor tipo toll |
| JP2017529353A (ja) | 2014-09-19 | 2017-10-05 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 |
| WO2016041925A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles |
| EP3194368B1 (en) | 2014-09-19 | 2020-12-23 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Benzo-heterocyclic compounds and their applications |
| JP2017535514A (ja) | 2014-09-19 | 2017-11-30 | バイエル ファーマ アクチエンゲゼルシャフト | Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類 |
| EA032401B1 (ru) | 2014-09-19 | 2019-05-31 | Байер Фарма Акциенгезельшафт | Бензилзамещенные индазолы в качестве ингибиторов bub1 |
| ES2964769T3 (es) | 2014-09-24 | 2024-04-09 | Exscientia Gmbh | Monocapa de PBMC o células de médula ósea y usos de la misma |
| CN104530415B (zh) | 2014-10-01 | 2017-09-01 | 厦门赛诺邦格生物科技股份有限公司 | 一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质 |
| CN104725628B (zh) | 2014-10-01 | 2018-04-17 | 厦门赛诺邦格生物科技股份有限公司 | 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质 |
| CN104530413B (zh) | 2014-10-01 | 2017-08-25 | 厦门赛诺邦格生物科技股份有限公司 | 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质 |
| EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
| UA125061C2 (uk) | 2014-10-06 | 2022-01-05 | Мерк Патент Ґмбг | Сполуки гетероарилу як інгібітори ткб і їх застосування |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| JP7023709B2 (ja) | 2014-10-14 | 2022-02-22 | リプタイド バイオサイエンス，インコーポレイテッド | 抗炎症特性を有するペプチド |
| WO2016061495A1 (en) | 2014-10-16 | 2016-04-21 | Predictive Therapeutics Ltd. | Atavarsitic systems and methods for biomarker discovery |
| EP3209780A4 (en) | 2014-10-24 | 2018-09-19 | University of Maryland, Baltimore | Short non-coding protein regulatory rnas (sprrnas) and methods of use |
| WO2016066634A2 (en) | 2014-10-27 | 2016-05-06 | Ruprecht-Karls-Universität Heidelberg | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
| DK3643709T3 (da) | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Inc | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf |
| MX382902B (es) * | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| EP3212668B1 (en) | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| US11236139B2 (en) * | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
| WO2016071477A1 (en) | 2014-11-07 | 2016-05-12 | Rheinische Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie | Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation |
| SG11201703464UA (en) | 2014-11-14 | 2017-05-30 | Novartis Ag | Antibody drug conjugates |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| JP2017537090A (ja) | 2014-11-17 | 2017-12-14 | ジェネンテック， インコーポレイテッド | Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法 |
| EA037519B1 (ru) | 2014-11-17 | 2021-04-07 | Селлектар Байосайенсиз, Инк. | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки |
| WO2016081732A1 (en) | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| PT3221306T (pt) | 2014-11-20 | 2020-02-19 | Merck Patent Gmbh | Compostos de heteroarilo como inibidores de irak e utilização dos mesmos |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US20180148789A1 (en) | 2014-12-01 | 2018-05-31 | University Of Southern California | Methods for treating and assessing tumor invasion and metastasis |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016087490A1 (en) | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2016087488A1 (en) | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives |
| WO2016087651A1 (en) | 2014-12-04 | 2016-06-09 | Emanuela Guerra | Humanized anti-trop-2 monoclonal antibodies and uses thereof |
| CA2968352A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
| EP3587417B9 (en) | 2014-12-09 | 2022-03-30 | Bayer AG | 1,3-thiazol-2-yl substituted benzamides |
| WO2016094309A1 (en) | 2014-12-10 | 2016-06-16 | Myosotis | Inhibition of tnf signaling in cancer immunotherapy |
| CN107003300B (zh) | 2014-12-12 | 2020-02-07 | 凯尔科迪股份有限公司 | 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法 |
| EP3233127A1 (de) | 2014-12-15 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern |
| WO2016100619A2 (en) | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| EP3233818A1 (en) | 2014-12-18 | 2017-10-25 | F. Hoffmann-La Roche AG | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| CR20170258A (es) | 2014-12-18 | 2017-07-21 | Bayer Pharma AG | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos. |
| KR20250044940A (ko) | 2014-12-18 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
| SI3234184T1 (sl) | 2014-12-19 | 2019-08-30 | Epigenomics Ag | Postopki za detekcijo CPG metilacije in za diagnosticiranje raka |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2016102493A1 (en) | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| JP6787899B2 (ja) | 2014-12-23 | 2020-11-18 | ベルゲンビオ アーエスアー | 医薬的活性化合物 |
| DE102014226903A1 (de) | 2014-12-23 | 2016-06-23 | Olympus Winter & Ibe Gmbh | HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe |
| JP2018500344A (ja) | 2014-12-23 | 2018-01-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | ６−ヒドロキシベンゾフラニル置換および６−アルコキシベンゾフラニル置換イミダゾピリダジン |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| EA032430B1 (ru) | 2014-12-24 | 2019-05-31 | Джилид Сайэнс, Инк. | Конденсированные пиримидины для лечения вич |
| SG11201705184PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| WO2016111947A2 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA2972846A1 (en) | 2015-01-08 | 2016-07-14 | Hackensack University Medical Center | Ex vivo methods for minimizing risks and maximizing benefits of allogeneic blood and marrow transplantation |
| US10053478B2 (en) | 2015-01-09 | 2018-08-21 | Reiley Pharmaceuticals, Inc. | COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers |
| WO2016117666A1 (ja) | 2015-01-23 | 2016-07-28 | 国立大学法人鹿児島大学 | Ｈｉｖ－１感染細胞殺傷剤及びその用途 |
| MX2017009571A (es) | 2015-01-23 | 2018-09-27 | Aclaris Therapeutics Inc | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. |
| SG11201705908VA (en) | 2015-01-28 | 2017-08-30 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| MX379425B (es) | 2015-01-30 | 2025-03-11 | Oncoceutics Inc | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia. |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| BR112017013677B1 (pt) | 2015-02-05 | 2023-11-21 | Merck Patent Gmbh | Compostos macrocíclicos como inibidores de irak1/4, seu processo de fabricação e seus usos, e composições farmacêuticas |
| CA2970550C (en) | 2015-02-06 | 2023-09-19 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
| JP7243021B2 (ja) | 2015-02-12 | 2023-03-22 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| CN107427501B (zh) | 2015-02-20 | 2023-12-01 | 第一三共株式会社 | 通过联合使用治疗癌症的方法 |
| PE20171789A1 (es) | 2015-03-02 | 2017-12-28 | Bristol Myers Squibb Co | Inhibidores del factor beta de crecimiento de transformacion (tgf-beta) |
| RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
| US10406162B2 (en) | 2015-03-09 | 2019-09-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations |
| MX2017011607A (es) | 2015-03-09 | 2018-04-10 | Bayer Pharma AG | Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. |
| US20180271891A1 (en) | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
| EP3268013B1 (en) | 2015-03-13 | 2021-10-13 | Fondazione Telethon | Il-10-producing cd4+ t cells for use in treating a cancer |
| US10946050B2 (en) | 2015-03-16 | 2021-03-16 | Imagilin Technology Llc | Compositions comprising probiotics and methods of use thereof |
| WO2016149366A1 (en) | 2015-03-16 | 2016-09-22 | The Johns Hopkins University | Methods and compositions for treating cancer |
| US10195237B2 (en) | 2015-03-16 | 2019-02-05 | Imagilin Technology Llc | Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| BR112017020002A2 (en) | 2015-03-20 | 2018-06-19 | Syndax Pharmaceuticals, Inc. | COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT |
| US20180044418A1 (en) | 2015-03-20 | 2018-02-15 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and vorinostat for treating cancer |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| US10745667B2 (en) | 2015-03-23 | 2020-08-18 | Yao Tang | Methods of primary tissue culture and drug screening using autologous serum and fluids |
| MX2017012131A (es) | 2015-03-25 | 2018-06-15 | Univ Michigan Regents | Composiciones y métodos para la administración de agentes de biomacromoléculas. |
| US10302629B2 (en) | 2015-03-30 | 2019-05-28 | University Of Maryland, Baltimore | Compositions and methods for treating cancer by rational targeting of protein translation |
| TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| KR102349475B1 (ko) | 2015-04-13 | 2022-01-11 | 화이자 인코포레이티드 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| WO2016166600A1 (en) | 2015-04-15 | 2016-10-20 | Trojantec Technologies Ltd | Delivery of microrna using mesenchymal stem cell microparticles |
| US10774047B2 (en) | 2015-04-17 | 2020-09-15 | The Trustees Of The University Of Pennsylvania | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy |
| CA2984357A1 (en) | 2015-04-29 | 2016-11-03 | Radius Pharmaceuticals, Inc. | Methods for treating cancer |
| US20180289685A1 (en) | 2015-04-30 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
| CA2984848A1 (en) | 2015-05-05 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2016187122A1 (en) | 2015-05-15 | 2016-11-24 | University Of Iowa Research Foundation | Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy |
| US20160339030A1 (en) | 2015-05-19 | 2016-11-24 | University Of Maryland, Baltimore | Treatment agents for inhibiting hiv and cancer in hiv infected patients |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184973A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016187508A2 (en) | 2015-05-20 | 2016-11-24 | The Broad Institute Inc. | Shared neoantigens |
| AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
| EP3297608B1 (en) | 2015-05-22 | 2022-07-13 | Aphios Corporation | Combination hiv therapeutic |
| JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| CN104892648A (zh) | 2015-05-27 | 2015-09-09 | 天津工业大学 | 一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途 |
| US20180164317A1 (en) | 2015-05-28 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Method for stratification of melanoma patients by determination of oxygen consumption, ppargc1a, ppargc1b and mitf levels |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| RU2718534C2 (ru) | 2015-06-05 | 2020-04-08 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl) |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| CN107810176B (zh) | 2015-06-08 | 2020-10-16 | 德国癌症研究公共权益基金会 | 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物 |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CA2989269C (en) | 2015-06-15 | 2020-09-22 | Robert Yongxin Zhao | Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| WO2016205566A1 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| WO2016205551A2 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| WO2016202756A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| WO2016202758A1 (en) | 2015-06-18 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds |
| EP3310168B1 (en) | 2015-06-19 | 2024-08-21 | Trustees of Boston University | Combinations of a nucleoside analog and an inducing agent for use in treating herpesvirus-induced conditions |
| CN107921144B (zh) | 2015-06-20 | 2023-11-28 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
| CN108025084B (zh) | 2015-06-22 | 2024-08-09 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| AU2016282724A1 (en) | 2015-06-23 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Targeted conjugates of KSP inhibitors |
| WO2016207098A1 (de) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-cd123-antikörpern |
| EP3313521A1 (de) | 2015-06-23 | 2018-05-02 | Bayer Pharma Aktiengesellschaft | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern |
| WO2016210247A1 (en) | 2015-06-24 | 2016-12-29 | Duke University | New methods of use for an anti-diarrhea agent |
| EP3313388A4 (en) | 2015-06-24 | 2019-05-15 | Duke University | CHEMICAL MODULATORS OF SIGNALING PATHS AND THERAPEUTIC USE |
| JP2018521058A (ja) | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| US9988391B2 (en) | 2015-06-29 | 2018-06-05 | Merck Patent Gmbh | TBK/IKK inhibitor compounds and uses thereof |
| RU2018103064A (ru) | 2015-06-29 | 2019-07-30 | Синдакс Фармасьютикалз, Инк. | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли |
| CA2990705A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| US10925852B2 (en) | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| UY36758A (es) | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| JP6700321B2 (ja) | 2015-07-04 | 2020-05-27 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 細胞結合分子の特異的共役体 |
| EP3319945B1 (en) | 2015-07-07 | 2021-04-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
| WO2017008046A1 (en) | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| WO2017005711A1 (de) | 2015-07-09 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | Phosphor- und schwefel-substituierte benzodiazepin-derivate |
| CN108137559B (zh) | 2015-07-09 | 2021-11-02 | 默克专利有限公司 | 用作btk抑制剂的嘧啶衍生物及其用途 |
| US10292961B2 (en) | 2015-07-15 | 2019-05-21 | Hangzhou Dac Biotech Co., Ltd. | Disulfur bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| CA2992364A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| TW201718495A (zh) | 2015-07-28 | 2017-06-01 | 貝塔貓製藥股份有限公司 | 蒽-9, 10-二酮二肟化合物前驅藥及其用途 |
| EP3124609A1 (en) | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| JP6334065B2 (ja) | 2015-07-29 | 2018-05-30 | 塩野義製薬株式会社 | キナゾリン誘導体の塩またはその結晶およびそれらの製造方法 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| EP3317401B1 (en) | 2015-07-29 | 2018-10-03 | Onkimmune Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| JP6949818B2 (ja) | 2015-07-31 | 2021-10-13 | バスキュラー バイオジェニックス リミテッド | 運動精子ドメイン含有タンパク質２及びがん |
| AR105592A1 (es) | 2015-08-03 | 2017-10-18 | Quadriga Biosciences Inc | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| WO2017023994A1 (en) | 2015-08-06 | 2017-02-09 | Yale University | Small molecule based antibody-recruiting compounds for cancer treatment |
| CA2993624A1 (en) | 2015-08-07 | 2017-02-16 | Thomas Helledays Stiftelse For Medicinsk Forskning | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma |
| WO2017025493A1 (en) | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Quinoline ezh2 inhibitors |
| WO2017027760A1 (en) | 2015-08-12 | 2017-02-16 | North Carolina State University | Platelet membrane-coated drug delivery system |
| WO2017031041A1 (en) | 2015-08-17 | 2017-02-23 | Channel Therapeutics, Inc. | Functionalized aminobenzoboroxoles |
| EP3133165A1 (en) | 2015-08-17 | 2017-02-22 | F. Hoffmann-La Roche AG | Methods for personalizing patient cancer therapy with anti angiogenic compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| WO2017034234A1 (ko) | 2015-08-21 | 2017-03-02 | 서울대학교 산학협력단 | Hdac 억제제 내성을 갖는 암 치료용 복합제제 |
| US20170056352A1 (en) | 2015-08-25 | 2017-03-02 | Rgenix, Inc. | PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF |
| WO2017035453A1 (en) | 2015-08-26 | 2017-03-02 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| EP3341373A1 (en) | 2015-08-26 | 2018-07-04 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| WO2017037022A1 (en) | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| WO2017040953A1 (en) | 2015-09-02 | 2017-03-09 | Wayne State University | Compositions and methods relating to rad6 inhibition |
| CN116893262A (zh) | 2015-09-02 | 2023-10-17 | 赛达克斯制药股份有限公司 | 用于组合疗法的患者的选择 |
| CN108348571B (zh) | 2015-09-03 | 2022-03-22 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| EP3350316B1 (en) | 2015-09-15 | 2024-05-08 | Stichting Radboud universitair medisch centrum | IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST |
| DE102015012049A1 (de) | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| DE102015012050A1 (de) | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| AU2016323612B2 (en) | 2015-09-18 | 2021-04-08 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and uses thereof |
| MX386726B (es) | 2015-09-18 | 2025-03-19 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. |
| RU2018114529A (ru) | 2015-09-20 | 2019-10-22 | Аир Кросс, Инк. | Озонолиз для активации соединений и деградации озона |
| KR20180087238A (ko) | 2015-09-21 | 2018-08-01 | 아이폼 - 폰다지오네 이스티튜토 에프아이알씨 디 온콜로지아 몰레콜레르 | 혈액암에 대한 새로운 치료 전략 |
| JP6863970B2 (ja) | 2015-09-21 | 2021-04-21 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環式化合物およびそれらの使用 |
| WO2017053823A1 (en) | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
| ES2963446T3 (es) | 2015-09-29 | 2024-03-27 | Kangpu Biopharmaceuticals Ltd | Composición farmacéutica y aplicación de la misma |
| NZ741785A (en) | 2015-09-30 | 2019-07-26 | Gilead Sciences Inc | 3-cyano-1h-1,2,4-triazol-1-yl compounds and uses thereof for the treatment of hiv |
| WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AU2016329075A1 (en) | 2015-10-02 | 2018-04-26 | Gilead Sciences, Inc. | Combinations of the BTK inhibitor GS-4059 with inhibitors selected from a JAK, ASK1, BRD and/or MMP9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| US10544156B2 (en) | 2015-10-02 | 2020-01-28 | Pierre Fabre Medicament | Hemi-synthetic trilobine analogs for use as a drug |
| KR20240158360A (ko) | 2015-10-09 | 2024-11-04 | 베링거 인겔하임 인터내셔날 게엠베하 | Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2017063966A1 (en) | 2015-10-13 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds |
| CN105288648B (zh) | 2015-10-14 | 2018-11-06 | 东南大学 | 一种亲水性药物的磷脂化合物、其药物组合物及应用 |
| US20180346877A1 (en) | 2015-10-15 | 2018-12-06 | Celularity, Inc. | Natural killer cells and ilc3 cells and uses thereof |
| WO2017063959A1 (de) | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren |
| AU2016340878A1 (en) | 2015-10-19 | 2018-05-10 | Dana-Farber Cancer Institute, Inc. | Polymerase Q as a target in HR-deficient cancers |
| HK1253320A1 (zh) | 2015-10-23 | 2019-06-14 | Daiichi Sankyo Company, Limited | 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法 |
| US20170115275A1 (en) | 2015-10-23 | 2017-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development |
| WO2017069289A1 (en) | 2015-10-23 | 2017-04-27 | Daiichi Sankyo Company, Limited | Dosage regimen of mdm2 inhibitor for treating cancers |
| EP3368687B1 (en) | 2015-10-27 | 2021-09-29 | The Broad Institute, Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| CN105457038A (zh) | 2015-11-09 | 2016-04-06 | 东南大学 | 一种速释型药物磷脂化合物及其药物组合物 |
| BR112018009361A8 (pt) | 2015-11-10 | 2019-02-26 | Univ Yale | composições e métodos para o tratamento de doenças autoimunes e de câncer |
| US11266727B2 (en) | 2015-11-12 | 2022-03-08 | Hookipa Biotech Gmbh | Arenavirus particles as cancer vaccines |
| WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| US10857156B2 (en) | 2015-11-20 | 2020-12-08 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
| WO2017091777A1 (en) | 2015-11-24 | 2017-06-01 | Vijay Krishnan | Novel healthcare delivery, treatment, and payment model for specialty drugs |
| BR112018011100A2 (en) | 2015-12-01 | 2018-12-04 | Genmab B.V. | antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition. |
| WO2017096246A1 (en) | 2015-12-03 | 2017-06-08 | Temple University-Of The Commonwealth System Of Higher Education | Modulation of nad+ and nad+ metabolic pathways for treatment of disease |
| US10654818B2 (en) | 2015-12-03 | 2020-05-19 | Bayer Pharma Aktiengesellschaft | Furane derivatives as inhibitors of ATAD2 |
| CN108603232A (zh) | 2015-12-03 | 2018-09-28 | 阿尔佛雷德医疗集团 | 监测骨髓瘤的治疗或进展 |
| WO2017093478A1 (en) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
| CN106821965A (zh) | 2015-12-04 | 2017-06-13 | 中国科学院大连化学物理研究所 | 一种维甲酸多药共递送纳米粒溶液及其制备和应用 |
| AU2016367306B2 (en) | 2015-12-09 | 2021-04-22 | Medizinische Universität Wien | Monomaleimide-functionalized platinum compounds for cancer therapy |
| US10969392B2 (en) | 2015-12-10 | 2021-04-06 | Vanderbilt University | Methods and systems for predicting response to immunotherapies for treatment of cancer |
| AU2016370591C1 (en) | 2015-12-15 | 2020-09-03 | Gilead Sciences, Inc. | Human immunodeficiency virus neutralizing antibodies |
| JP2019504826A (ja) | 2015-12-16 | 2019-02-21 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
| EP3889146A1 (en) | 2015-12-17 | 2021-10-06 | Merck Patent GmbH | Polyheterocyclic tlr7/8 antagonists and their uses for treating immune disorders |
| CA3006772A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| BR112018012138A2 (pt) | 2015-12-17 | 2018-12-04 | Novartis Ag | moléculas de anticorpo para pd-1 e usos das mesmas |
| UY37030A (es) | 2015-12-18 | 2017-07-31 | Novartis Ag | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |
| WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| US20200268720A1 (en) | 2015-12-22 | 2020-08-27 | Glaxosmithkline Llc | Methods of use of a class iia hdac inhibitor |
| CA3048204A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response |
| US20190290759A1 (en) | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| EP3397263B1 (en) | 2015-12-30 | 2023-09-20 | Celgene Corporation | T lymphocyte production methods and t lymphocytes produced thereby |
| US10189797B2 (en) | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| EP3400009A2 (en) | 2016-01-05 | 2018-11-14 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
| MX2018008413A (es) | 2016-01-08 | 2019-02-20 | Replimune Ltd | Virus oncolitico modificado. |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| US10729680B2 (en) | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| CN108472259A (zh) | 2016-01-19 | 2018-08-31 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
| US11963520B2 (en) | 2016-01-19 | 2024-04-23 | Celgene Corporation | Transgenic mouse expressing human cereblon |
| WO2017132541A1 (en) | 2016-01-27 | 2017-08-03 | University Of Maryland, Baltimore | A method for monitoring cancer and for regulation of semaphorin 4d to improve cancer immunotherapy regimens |
| BR112018015291A2 (pt) | 2016-01-28 | 2018-12-18 | Univ Indiana Res & Tech Corp | uso de inibidores de histona desacetilase para melhorar imunoterapias |
| HRP20210198T1 (hr) | 2016-01-29 | 2021-04-16 | Epigenomics Ag | Postupci detektiranja metiliranja cpg u dna dobivene iz tumora u uzorcima krvi |
| EP3411498A1 (en) | 2016-02-01 | 2018-12-12 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| GB201601773D0 (en) | 2016-02-01 | 2016-03-16 | Renishaw Plc | Method |
| BR112018015782A2 (pt) | 2016-02-01 | 2019-01-02 | Bayer Pharma AG | biomarcadores de copanlisibe |
| EP3411063B1 (en) | 2016-02-02 | 2020-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
| WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
| HK1259487A1 (zh) | 2016-02-04 | 2019-11-29 | Hangzhou Dac Biotech Co. Ltd. | 特定的共轭连接子，特定的免疫共轭物，制造和使用这些共轭物的方法 |
| CN108883112B (zh) | 2016-02-05 | 2022-07-26 | 拜耳医药股份公司 | 用于癌症患者分级和癌症治疗的化合物、组合物和方法 |
| CN108778267A (zh) | 2016-02-08 | 2018-11-09 | 万春药业公司 | 包含妥卡雷琐或其类似物的组合物 |
| WO2017139623A1 (en) | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
| WO2017143237A1 (en) | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| WO2017143035A2 (en) | 2016-02-17 | 2017-08-24 | The Penn State Research Foundation | Method and therapeutic use of pign and other genes or genes products that pign interacts with for prognosis and treatment of hematological neoplasias |
| WO2017144543A1 (en) | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| WO2017145162A1 (en) | 2016-02-23 | 2017-08-31 | Chaya Brodie | Generation of cancer stem cells and use thereof |
| US20170247690A1 (en) | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Oncoviral treatment with nuclease and chemotherapeutic |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| JP7157981B2 (ja) | 2016-03-07 | 2022-10-21 | チャールストンファーマ， エルエルシー | 抗ヌクレオリン抗体 |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| WO2017156147A1 (en) | 2016-03-08 | 2017-09-14 | The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management Technology Development Center | Immune boosting dietary compounds for disease control and prevention |
| WO2017160761A2 (en) | 2016-03-14 | 2017-09-21 | Kiromic, Inc. | Compositions and methods for treating cancers |
| US20190077856A1 (en) | 2016-03-15 | 2019-03-14 | Memorial Sloan Kettering Cancer Center | Method of treating diseases using kinase modulators |
| WO2017157418A1 (en) | 2016-03-15 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Combination of mknk1-inhibitors |
| US20170268001A1 (en) | 2016-03-16 | 2017-09-21 | The University Of Chicago | Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| JP6937775B2 (ja) | 2016-03-18 | 2021-09-22 | プロセプト バイオロボティクス コーポレイション | 出血閉鎖組織体積における止血のための低侵襲方法およびシステム |
| US20170273926A1 (en) | 2016-03-24 | 2017-09-28 | Orbus Therapeutics, Inc. | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN105949114A (zh) | 2016-06-27 | 2016-09-21 | 山东川成医药股份有限公司 | 一种西达本胺的合成方法 |
| WO2018016563A1 (en) | 2016-07-20 | 2018-01-25 | Eisai R&D Management Co., Ltd. | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
| CN106866571B (zh) | 2017-01-20 | 2018-06-29 | 中国药科大学 | 杂环脲类化合物及其药物组合物和应用 |
| AU2017202864B2 (en) | 2017-02-13 | 2020-04-23 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| CN107011238B (zh) | 2017-03-14 | 2020-05-01 | 北京化工大学 | 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途 |
| AU2018273958B2 (en) | 2017-05-25 | 2022-07-21 | Leidos, Inc. | PD-1 and CTLA-4 dual inhibitor peptides |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
-
2017
- 2017-05-10 TW TW106115474A patent/TWI794171B/zh active
- 2017-05-11 AU AU2017264857A patent/AU2017264857B2/en active Active
- 2017-05-11 WO PCT/US2017/032200 patent/WO2017197140A1/en not_active Ceased
- 2017-05-11 EP EP17796856.7A patent/EP3454843A4/en active Pending
- 2017-05-11 JP JP2018559885A patent/JP7013388B2/ja active Active
- 2017-05-11 MA MA044990A patent/MA44990A/fr unknown
- 2017-05-11 NZ NZ748058A patent/NZ748058A/en unknown
- 2017-05-11 US US15/592,929 patent/US10385131B2/en active Active
- 2017-05-11 EA EA201892581A patent/EA201892581A1/ru unknown
- 2017-05-11 MX MX2018013593A patent/MX390986B/es unknown
- 2017-05-11 KR KR1020227029531A patent/KR20220123742A/ko not_active Ceased
- 2017-05-11 KR KR1020187035902A patent/KR102471590B1/ko active Active
- 2017-05-11 CN CN201780042391.5A patent/CN109640985A/zh active Pending
- 2017-05-11 CA CA3023546A patent/CA3023546A1/en active Pending
- 2017-05-11 BR BR112018073328-8A patent/BR112018073328A2/pt not_active Application Discontinuation
-
2018
- 2018-11-06 IL IL262808A patent/IL262808B2/en unknown
- 2018-11-07 MX MX2022001447A patent/MX2022001447A/es unknown
-
2019
- 2019-08-14 US US16/541,020 patent/US11535670B2/en active Active
-
2021
- 2021-10-12 JP JP2021167100A patent/JP7190548B2/ja active Active
-
2022
- 2022-04-27 AU AU2022202748A patent/AU2022202748A1/en not_active Abandoned
- 2022-11-23 US US17/993,567 patent/US20230151099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201808286A (zh) | 2018-03-16 |
| TWI794171B (zh) | 2023-03-01 |
| JP7190548B2 (ja) | 2022-12-15 |
| EP3454843A1 (en) | 2019-03-20 |
| CA3023546A1 (en) | 2017-11-16 |
| JP2022017295A (ja) | 2022-01-25 |
| NZ748058A (en) | 2025-06-27 |
| EA201892581A1 (ru) | 2019-06-28 |
| IL262808A (en) | 2018-12-31 |
| AU2017264857B2 (en) | 2022-05-12 |
| EP3454843A4 (en) | 2020-01-01 |
| IL262808B2 (en) | 2023-07-01 |
| MX2022001447A (es) | 2022-02-22 |
| KR20190022520A (ko) | 2019-03-06 |
| AU2017264857A1 (en) | 2018-11-29 |
| MX390986B (es) | 2025-03-21 |
| US20230151099A1 (en) | 2023-05-18 |
| JP7013388B2 (ja) | 2022-01-31 |
| US20170327583A1 (en) | 2017-11-16 |
| WO2017197140A1 (en) | 2017-11-16 |
| KR102471590B1 (ko) | 2022-11-29 |
| US11535670B2 (en) | 2022-12-27 |
| BR112018073328A2 (pt) | 2019-02-26 |
| JP2019518741A (ja) | 2019-07-04 |
| CN109640985A (zh) | 2019-04-16 |
| US10385131B2 (en) | 2019-08-20 |
| AU2022202748A1 (en) | 2022-05-19 |
| US20200181267A1 (en) | 2020-06-11 |
| MA44990A (fr) | 2021-04-07 |
| IL262808B1 (en) | 2023-03-01 |
| MX2018013593A (es) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250026832A1 (en) | Combination therapies of hdac inhibitors and pd-1 inhibitors | |
| US20230151099A1 (en) | Combination therapies of hdac inhibitors and pd-l1 inhibitors | |
| US20200383961A1 (en) | Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors | |
| US20220110924A1 (en) | Methods and compositions for genetic modulation of tumor microenvironments | |
| KR20250134694A (ko) | 심장 내약성 hdac 억제제를 포함하는 방법 및 조성물 | |
| HK40008034B (en) | Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor | |
| HK40008034A (en) | Treatment of colon cancer with a combination of the hdac inhibitor hbi-8000 and a pd-l1 inhibitor | |
| EA045229B1 (ru) | Комбинация ингибиторов hdac и pd-1 и её применение для лечения рака толстой кишки | |
| BR122024004327A2 (pt) | Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto | |
| BR122024004326A2 (pt) | Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220825 Application number text: 1020187035902 Filing date: 20181211 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220916 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230502 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20231004 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230502 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |